AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03472521
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match gabapentin
Trial: NCT00343629
Drug: sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03448172
Drug: [14C]PF-05221304
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single oral dose of \[14C\]PF-05221304 (50 mg/100 µCi liquid formulation)
Trial: NCT02076815
Drug: Thromboreductin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overencapsulated capsule, twice daily, 2-12 weeks titration to achieve the stable platelet count, followed by 4 more weeks
Trial: NCT04229771
Drug: Proparacaine Hydrochloride ophthalmic solution, USP 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop instilled in one eye, randomly chosen, as topical anesthetic
Trial: NCT01476800
Drug: YM178 OCAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00625183
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00042653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of placebo taken once daily orally 60 mg of placebo taken once daily orally 90 mg of placebo taken once daily orally 120 mg of placebo taken once daily orally 180 mg of placebo taken once daily orally
Trial: NCT00082095
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Type=exact number, unit=mg, number=500, form=tablet, route=oral. Capecitabine will be administered at a dosage of 1000 mg/m2 twice daily for 14 consecutive days followed by a 7-day rest period. Cycle is repeated every 21 days, up to one year.
Trial: NCT00198809
Drug: Biolean + Diet education
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00198809
Drug: Biolean Free + Diet education
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00198809
Drug: Placebo + Diet education
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01990768
Drug: 2 grams TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
Trial: NCT04539548
Drug: Dextenza Ophthalmic Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4mg insert for intracanalicular use
Trial: NCT03116009
Drug: Screening for diabetes with 1-hour GCT and HbA1
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: They will receive 50gm oral glucose tolerance test before 20 weeks and if abnormal, they will do the diagnostic test with 100gm OGTT with HbA1C.
Trial: NCT01526278
Drug: Maxmarvil®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug : Maxmarvil® 1tablet one time in clinical trial, PO medication
Trial: NCT01153009
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching capsules
Trial: NCT00401193
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01048944
Drug: Placebo Patch and Placebo Pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 encapsulated placebo pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down. Placebo patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days. The placebo patches were given beginning 1st day cessation: 21 mg size (but actually placebo)/24 days, 14 mg size (actually placebo)/ 14 mg size (actually placebo) 14 days/, 7 mg size (actually placebo)/7 days
Trial: NCT01709864
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
Trial: NCT03250338
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally
Trial: NCT02660684
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injection
Trial: NCT01613079
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate 7.5-12.5mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 12.5mg（max 0.3mg/Kg） per week in 4 weeks. Folic acid at the dose of 10mg per week were applied to all patients.
Trial: NCT00910117
Drug: PF regimen (cisplatin and 5-FU)
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisplatin 75 mg/m2 d1 and 5-FU 750 mg/m2/d CIV d1-5
Trial: NCT02802696
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single bolus dose of 2 mL normal saline will be given intravenously immediately within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.
Trial: NCT03372382
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NSAID
Trial: NCT03372382
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: analgesic
Trial: NCT02153125
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00481364
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tb/day
Trial: NCT00020202
Drug: FR901228
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04557436
Drug: PBLTT52CAR19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gene therapy
Trial: NCT00004464
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03251482
Drug: JNJ-64179375 A mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-64179375 Dose A mg/kg IV as a single dose on Day 1.
Trial: NCT03251482
Drug: JNJ-64179375 C mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-64179375 Dose C mg/kg IV as a single dose on Day 1.
Trial: NCT03251482
Drug: JNJ-64179375 D mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-64179375 Dose D mg/kg IV as a single dose on Day 1.
Trial: NCT03251482
Drug: Placebo JNJ-64179375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching JNJ-64179375 placebo (normal saline) administered as IV infusion as a single dose on Day 1.
Trial: NCT04661852
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV, over 30 minutes (schedule based upon dose level)
Trial: NCT00561587
Drug: Seroquel®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage form: oral, adjusted in the range of 25 to max. 300 mg /day
Trial: NCT01360853
Drug: ON 01910.Na
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ON 01910.Na, 1800 mg/m2 via 2 hr CIV infusions administered twice weekly for 3 weeks of a 4 week cycle.
Trial: NCT02849886
Drug: Dimerizer drug AP1903
RxNorm normalized name: dimer dilinoleyl dimer dilinoleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP1903 drug will be administrated at a dose of 0.4 mg/kg by intravenous route in the two following cases:~* Acute Grade ≥II or symptomatic Grade I GvHD justifying systemic immunosuppression therapy;~* Grade ≥3 toxicity attributable to GMC.
Trial: NCT01220726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection
Trial: NCT06178718
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Placebo will be administered once in each group.
Trial: NCT02878096
Drug: [14C]-SK-1404
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part 1, each subject will receive a single PO dose of SK-1404 followed by an IV microtracer dose of \[14C\]-SK-1404.
Trial: NCT01502956
Drug: Botox® injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects will complete baseline assessments, be randomized and scheduled for Botox A® injection visit. Subjects who received a Botox A® injection will be assessed for a clinical response, at 1 month from injection, using the same clinical criterion (≥50% improvement in the mean number of UUIE/day on a 3 day bladder diary completed prior to the 1 month visit). Those subjects that experience a clinical response, at one month, will be eligible for a repeat Botox A® injection after 6 months, if they experience degradation of clinical effect, using the PGSC.
Trial: NCT04392219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1:~Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo.~Part 3:~Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo.
Trial: NCT00449917
Drug: vitamins
RxNorm normalized name: Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04449276
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive an intramuscular injection by needle in the deltoid area.
Trial: NCT01709968
Drug: MAGNOX 520®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: un-organic granular magnesium complex, composed of Magnesium Oxide \& Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks
Trial: NCT01709968
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similarly looking placebo. Oral administration once daily for 4 weeks
Trial: NCT00088972
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00857467
Drug: NRL001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 1 g rectal suppository, with a 7-day washout period between dosing.
Trial: NCT00857467
Drug: NRL001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 2 g rectal suppository, with a 7-day washout period between dosing.
Trial: NCT00214214
Drug: Campath 1H® (Alemtuzumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02210325
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01915550
Drug: Humulin Insulin Mixtard
RxNorm normalized name: insulin isophane / insulin, regular, human Pen Injector [Humulin]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00619372
Drug: OKT3, GC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
Trial: NCT00619372
Drug: OKT3, GC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
Trial: NCT03594955
Drug: SAR440234
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:lyophilisate to be resuspended in solution Route of administration: intravenous
Trial: NCT00495690
Drug: Oral zinc gluconate (5 mg elemental)
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each infant in the study received placebo or 5 mg of elemental zinc (1 RDA) as zinc acetate syrup once daily from 4 weeks of age till 6 months of age.
Trial: NCT03446209
Drug: 0.9% physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental arm's patients will obtain saline intravenously once every 4 weeks for 16 weeks. If necessary, patients will get rescue medication after week 16 to week 28.
Trial: NCT01680952
Drug: B) CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Extended Release Tacrolimus (Advagraf®)~   : Same as above.~2. Mycophenolate mofetil : After surgery : 500mg/kg po. within 24hrs after reperfusion. After that, daily dose: 1000mg bid
Trial: NCT01584505
Drug: CHF1535 + CHF5992 dose 1 BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF1535 + CHF5992 dose 1 BID for 14 days
Trial: NCT01584505
Drug: CHF1535 + CHF5992 dose2 BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF1535 + CHF5992 dose 2 BID for 14 days
Trial: NCT01584505
Drug: CHF1535 daily dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF1535 daily dose for 14 days
Trial: NCT00504543
Drug: AEB071
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, twice daily
Trial: NCT00815503
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT01247675
Drug: ACP-001 (TransCon hGH)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: s.c., weekly injection
Trial: NCT00621725
Drug: AZD2171
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose
Trial: NCT03718234
Drug: Subcutaneous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will be monitored and receive an interval bolus SQHC dosing regimen that more closely mimics cortisol, 17OHP and D4A circadian and ultradian rhythms than conventional oral HC dosing.
Trial: NCT03718234
Drug: Standard glucocorticoid therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this arm will continue on standard oral hydrocortisone therapy
Trial: NCT01090050
Drug: Naproxen Sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
Trial: NCT02933528
Drug: DSXS Topical product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily for 28 days
Trial: NCT03539484
Drug: RO7172508
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7172508 was administered at a dose and as per the schedule specified in the respective arms.
Trial: NCT02983461
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet, 3 times a day for 10 weeks
Trial: NCT02256735
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritobegron Cl (KUC 7483 CL) tablets low dose
Trial: NCT02256735
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02256735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02496039
Drug: NUEDEXTA®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUEDEXTA® only
Trial: NCT02699827
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive epidural 5 ml saline 0.9%
Trial: NCT02103699
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. Patients receiving simeprevir (single capsule of 150 mg once daily) as prescribed by the health care provider will be observed.
Trial: NCT03374488
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered orally twice daily.
Trial: NCT05386290
Drug: conventional treatment (glucocoticoid, immunosupressive drugs and/or mesalazine)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment includes glucocoticoid, immunosupressive drugs and/or mesalazine. Immunosupressive drugs include azathioprine (AZA), methotrexate (MTX) and thalidomide (THA).
Trial: NCT01005901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation capsules were provided for use via a SDDPI
Trial: NCT04430088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of 0 mg of VVZ-149
Trial: NCT03201965
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive 300 mg/m\^2 of cyclophosphamide as an oral or IV dose.
Trial: NCT00338221
Drug: glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02608242
Drug: YH22189
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02608242
Drug: Twynsta 80/10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00243971
Drug: SPM 962
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00272844
Drug: crystalline cholesterol oil-based suspension
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/mL suspension of crystalline cholesterol in oil. Dosage (generally 75-300 mg/kg/day in divided doses) is based on initial cholesterol levels and regulated to increase, yet maintain, cholesterol levels no higher than normal ranges.
Trial: NCT00893139
Drug: AL-38583 ophthalmic solution 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00893139
Drug: AL-38583 ophthalmic solution 0.10%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02088398
Drug: ACY-1215
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01690195
Drug: ABT-126
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT01263717
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2mg daily given by subcutaneous injection for the first 6 months of the study, followed by an open-label phase of 6 months of tesamorelin (growth hormone releasing hormone) treatment, 2mg daily given by subcutaneous injection
Trial: NCT03696199
Drug: Long-Acting Local Anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The cocktail consists of:~* 0.5% Ropivicaine, 24.6 mL~* Clonidine 100 mcg/mL, 0.4mL~* Epinephrine 1mg/mL, 0.5mL~* Saline to total volume of 50 mL (24.5mL of saline)~The total amount of solution prepared is 50mL, but typically 30mL is used based on the size of the incision. The total volume administered will be recorded.
Trial: NCT03696199
Drug: Regional Anesthesia
RxNorm normalized name: ACL6SP45 REGIONAL ANESTHESIA KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ropivicaine - 30mL each sciatic and femoral/saphenous nerve, ultrasound guided
Trial: NCT00933985
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01397149
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form, frequency and duration exactly as experimental arm.
Trial: NCT01664507
Drug: conventional dose epinephrine
RxNorm normalized name: epinephrine Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional dose epinephrine : 0.5mg/kg + 0.9% normal saline
Trial: NCT01664507
Drug: low dose epinephrine
RxNorm normalized name: epinephrine Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low dose epineprhine : 0.1mg/kg + 0.9% normal saline
Trial: NCT04513171
Drug: Norditropin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norditropin 245μg/kg/week, subcutaneous injection, Once daily.
Trial: NCT03131687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03945318
Drug: BION-1301 Single Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A solution for IV infusion administered as a single dose.
Trial: NCT03945318
Drug: Placebo Single Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A solution by IV infusion administered as a single dose.
Trial: NCT03945318
Drug: BION-1301 Multiple Doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A solution for IV infusion or SC injections (Part 3 only) administered as multiple doses.
Trial: NCT03945318
Drug: Placebo Multiple Doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A solution by IV infusion administered as multiple doses.
Trial: NCT03945318
Drug: BION-1301 Single Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injection administration as a single dose using vials or pre-filled syringes (PFS) (Part 4 only).
Trial: NCT02853071
Drug: standard practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard practice
Trial: NCT00002773
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00635986
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mcg Fentanyl intravenous or epidural route
Trial: NCT00006390
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02088892
Drug: BCG Tice
RxNorm normalized name: BCG TICE 50MG/AMP VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection
Trial: NCT02482753
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally twice per week (BIW)
Trial: NCT06454643
Drug: Flucloxacillin and gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention aimed to investigate the effectiveness of administering gentamicin in reducing the incidence of SSI.
Trial: NCT02875717
Drug: low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03231397
Drug: Assess AAA rupture risk by PET-CTA scans
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assess AAA rupture risk by PET-CTA scans